Clinical Trials Logo

Clinical Trial Summary

Rationale: Dual antiplatelet therapy, consisting of aspirin and a P2Y12-inhibitor, reduces the risk of stent thrombosis, myocardial infarction and stroke after coronary stent implantation. Inevitably, it is also associated with a higher risk of (major) bleeding. Given the advances in stent properties, stenting implantation technique and pharmacology, it may be possible to treat patients with a single antiplatelet strategy completely omitting aspirin. Objective: This study will assess whether omitting aspirin reduces the rate of major or minor bleeding while remaining non-inferior to the current standard of care with regards to net clinical adverse events and ischemic events in patients with non-ST segment elevation acute coronary syndrome. Study design: Open-label, multicentre randomized controlled trial. Study population: Adult patients presenting with non-ST segment elevation acute coronary syndrome planned for percutaneous coronary intervention. Intervention: In the intervention group aspirin will be completely omitted from the antiplatelet regimen in the 12 months following PCI. Main study parameters/endpoints: The primary net adverse clinical endpoint is defined as the composite of all-cause death, myocardial infarction, stroke and Bleeding Academic Research Consortium type 3 or 5 bleeding at 12 months. The primary bleeding endpoint is major or minor bleeding defined as Bleeding Academic Research Consortium type 2, 3 or 5 bleeding at 12 months. The primary ischemic endpoint is ischemic events defined as the composite of all-cause death, myocardial infarction and stroke at 12 months.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT05125276
Study type Interventional
Source Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Status Not yet recruiting
Phase Phase 4
Start date March 2022
Completion date March 2025

See also
  Status Clinical Trial Phase
Active, not recruiting NCT02892903 - In the Management of Coronary Artery Disease, Does Routine Pressure Wire Assessment at the Time of Coronary Angiography Affect Management Strategy, Hospital Costs and Outcomes? N/A
Recruiting NCT05117866 - Acetyl Salicylic Elimination Trial JAPAN: The ASET JAPAN Pilot Study N/A
Recruiting NCT02578537 - COmparison of the Pharmacodynamics and Pharmacokinetics Ticagrelor Versus Clopidogrel in Patients With CKD and NSTE-ACS Phase 4
Withdrawn NCT03300167 - Study of the Vascular Response to Percutaneous Coronary Intervention in Patients With Non-ST-elevation Acute Coronary Syndromes Using Intravascular Blood Sampling N/A
Terminated NCT02071966 - Study of Effects of Ticagrelor on Microparticles and Micro-RNA in NSTE-ACS Phase 4
Recruiting NCT03863327 - EKG Criteria and Identification of Acute Coronary Occlusion
Recruiting NCT04400500 - Differential Diagnosis and Risk Stratification in Patients With Suspected NSTEACS
Completed NCT01962428 - Different LD of Ticagrelor for Antiplatelet Effect in Patients With Non-ST-segment Elevation ACS Undergoing PCI Phase 4
Recruiting NCT04476173 - ANalgesic Efficacy and Safety of MOrphiNe Versus Methoxyflurane in Patients With Acute Myocardial Infarction Phase 3
Active, not recruiting NCT02073565 - HARMONEE - Japan-USA Harmonized Assessment by Randomized, Multi-Center Study of OrbusNEich's Combo StEnt N/A
Recruiting NCT04766437 - Optical Coherence Tomography-Guided PCI With Single-Antiplatelet Therapy Phase 2
Recruiting NCT02415803 - Safety and Efficacy of Low-Dose Ticagrelor in Chinese Patients With NSTE-ACS Phase 3